<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Unipolar depression in adults: Treatment with lithium
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Unipolar depression in adults: Treatment with lithium
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Unipolar depression in adults: Treatment with lithium
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Michael Gitlin, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Peter P Roy-Byrne, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            David Solomon, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Mar 15, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H15952998">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          Lithium
         </a>
         is mainly used to treat bipolar disorder, which is characterized by recurrent episodes of depression, mania, and hypomania. However, lithium is also used as an adjunctive medication in patients who have inadequately responded to an antidepressant for treatment of unipolar depression (ie, depression with no lifetime history of mania or hypomania) [
         <a href="#rid1">
          1
         </a>
         ]. In addition, lithium is used as monotherapy to treat acute episodes of unipolar depression and as maintenance treatment to prevent recurrence of unipolar depressive episodes.
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          Lithium
         </a>
         was first used by psychiatrists in the mid-1800s [
         <a href="#rid2">
          2
         </a>
         ]. The first controlled trial of lithium for unipolar depression was in 1968.
        </p>
        <p>
         This topic reviews the use of
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         as adjunctive treatment and as monotherapy for acute episodes and maintenance treatment of unipolar depression. Treatment-resistant depression and the use of lithium to treat bipolar disorder are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/14685.html" rel="external">
          "Unipolar depression in adults: Choosing treatment for resistant depression"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/680.html" rel="external">
          "Bipolar disorder in adults: Choosing maintenance treatment", section on 'Lithium'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H11208494">
         <span class="h1">
          ADD-ON LITHIUM FOR TREATMENT-RESISTANT DEPRESSION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The most common use of
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         in patients with unipolar depression is to augment an antidepressant that does not adequately treat a depressive syndrome. Lithium or an alternative adjunctive agent is often necessary because remission with antidepressant monotherapy occurs in only 28 to 47 percent of patients, even with an optimal trial [
         <a href="#rid3">
          3-5
         </a>
         ]. It is commonly thought that augmentation is more effective for patients who initially have a partial response to antidepressant monotherapy, compared with patients who do not respond at all, but this is not established [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3473158985">
         <span class="h2">
          Efficacy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Results from high-quality studies consistently support using add-on
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         for acutely depressed patients who do not fully respond to an antidepressant [
         <a href="#rid7">
          7
         </a>
         ]. As an example, four meta-analyses of randomized trials have compared lithium with placebo as an adjunct to antidepressants in patients with treatment-resistant depression (pooled sample sizes ranging from approximately 250 to 650) [
         <a href="#rid8">
          8-11
         </a>
         ]. Lithium was commonly administered at a dose of 800 or 900 mg/day, in trials that lasted on average three weeks. Results from the meta-analyses included the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Response (reduction of baseline symptoms ≥50 percent) was generally three times more likely to occur with adjunctive
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         than placebo (odds ratio 3) [
         <a href="#rid8">
          8-10
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          Lithium
         </a>
         provided one more response than placebo for every five patients treated with each regimen (number needed to treat of five) [
         <a href="#rid8">
          8,11
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Subgroup analyses found that
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         was efficacious for augmenting either first-generation antidepressants (eg, tricyclics) or second-generation antidepressants (eg, selective serotonin reuptake inhibitors [SSRIs]) [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Tolerability varied across studies, such that discontinuation of treatment due to adverse effects was:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Comparable with
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         and placebo [
         <a href="#rid8">
          8
         </a>
         ]
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Greater with
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         than placebo (odds ratio 2) [
         <a href="#rid9">
          9
         </a>
         ]
        </p>
        <p>
        </p>
        <p>
         There are no established predictors of response to adjunctive
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         in patients with unipolar depression. One study suggests a more robust response to adjunctive lithium in geriatric versus nongeriatric depressed patients [
         <a href="#rid12">
          12
         </a>
         ]. Although it is generally thought that adjunctive lithium is equally effective with all antidepressants, one small study suggests that lithium is more effective when it is added to
         <a class="drug drug_general" data-topicid="10042" href="/z/d/drug information/10042.html" rel="external">
          venlafaxine
         </a>
         , rather than
         <a class="drug drug_general" data-topicid="8554" href="/z/d/drug information/8554.html" rel="external">
          imipramine
         </a>
         [
         <a href="#rid13">
          13
         </a>
         ].
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          Lithium
         </a>
         augmentation may reduce the risk of completed suicide in patients with unipolar depression. (See
         <a class="medical medical_review" href="/z/d/html/1708.html" rel="external">
          "Suicidal ideation and behavior in adults", section on 'Pharmacotherapy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2757307">
         <span class="h3">
          Compared directly with other drugs
         </span>
         <span class="headingEndMark">
          —
         </span>
         Only a few head-to-head, randomized trials have compared the efficacy of
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         with other drugs for augmenting an antidepressant that has inadequately treated a depressive syndrome. The limited data suggest that lithium is comparable to T3 (triiodothyronine) or a second antidepressant.
        </p>
        <p>
         Other medications are used more often than
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         as augmentation, despite the robust evidence supporting adjunctive lithium. A study examined a pharmacy database that included nearly 250,000 patients with unipolar depression and found that more patients received a second antidepressant, an antipsychotic, or an anticonvulsant as augmentation compared with lithium (10.9 versus 7.3 versus 3.7 versus 0.5 percent of all patients) [
         <a href="#rid14">
          14
         </a>
         ]. This may reflect the perception that lithium often causes side effects and long-term toxicity. In addition, clinicians must monitor serum lithium levels, renal function tests, and thyroid function tests. (See
         <a class="medical medical_review" href="/z/d/html/2358.html" rel="external">
          "Renal toxicity of lithium"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7843.html" rel="external">
          "Lithium and the thyroid"
         </a>
         .)
        </p>
        <p>
         Use of second-generation antipsychotics as add-on therapy to treat unipolar, nonpsychotic major depression that is unresponsive to an antidepressant is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/14688.html" rel="external">
          "Unipolar depression in adults: Treatment with second-generation antipsychotics"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2757334">
         <span class="h4">
          Triiodothyronine (T3)
         </span>
         <span class="headingEndMark">
          —
         </span>
         Two head-to-head randomized trials found that
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         was comparable to triiodothyronine (T3) for augmenting a tricyclic antidepressant,
         <a class="drug drug_general" data-topicid="8874" href="/z/d/drug information/8874.html" rel="external">
          citalopram
         </a>
         ,
         <a class="drug drug_general" data-topicid="9886" href="/z/d/drug information/9886.html" rel="external">
          sertraline
         </a>
         ,
         <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">
          bupropion
         </a>
         , or
         <a class="drug drug_general" data-topicid="10042" href="/z/d/drug information/10042.html" rel="external">
          venlafaxine
         </a>
         in patients with unipolar major depression [
         <a href="#rid15">
          15,16
         </a>
         ]. One trial compared lithium, T3, and placebo in 50 patients who did not respond to
         <a class="drug drug_general" data-topicid="9329" href="/z/d/drug information/9329.html" rel="external">
          desipramine
         </a>
         or
         <a class="drug drug_general" data-topicid="8554" href="/z/d/drug information/8554.html" rel="external">
          imipramine
         </a>
         and found that response (improvement from baseline on the depression rating scale ≥ 50 percent) occurred in significantly more patients who received adjunctive lithium or T3, compared with placebo (53 and 59 versus 19 percent); there was no significant difference between lithium and T3 [
         <a href="#rid16">
          16
         </a>
         ]. The second trial was open label and compared lithium with T3 in 73 patients who prospectively failed antidepressant monotherapy; there was no significant difference in the proportion of patients who remitted with either adjunctive lithium or T3 (16 versus 25 percent) nor in time to remission [
         <a href="#rid15">
          15
         </a>
         ]. However, withdrawal from treatment because of side effects was significantly greater for patients who received lithium compared with patients who received T3
         <sub>
         </sub>
         (23 versus 10 percent).
        </p>
        <p>
         Use of T3 as add-on therapy to treat unipolar, nonpsychotic major depression that is unresponsive to an antidepressant is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/15722.html" rel="external">
          "Unipolar depression in adults: Augmentation of antidepressants with thyroid hormone"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2757341">
         <span class="h4">
          Antidepressants
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with unipolar major depression, it is not clear if add-on treatment with
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         is comparable or inferior to add-on treatment with a second antidepressant due to the limited evidence:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Two head-to-head randomized trials found that low-dose
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         (300 to 600 mg per day) was comparable to low-dose
         <a class="drug drug_general" data-topicid="9329" href="/z/d/drug information/9329.html" rel="external">
          desipramine
         </a>
         (25 to 50 mg per day) as augmentation [
         <a href="#rid17">
          17,18
         </a>
         ]. In each trial, patients who had a partial response or no response to eight weeks of treatment with
         <a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">
          fluoxetine
         </a>
         (20 mg per day) were assigned to lithium plus fluoxetine or to desipramine plus fluoxetine for four weeks. The proportion of patients who remitted in the two trials was similar in the groups who received lithium augmentation compared with the groups who received desipramine augmentation (29 and 24 versus 25 and 29 percent). Trials comparing therapeutic doses of these medications have not been conducted.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A 10-week, open-label randomized trial compared add-on
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         with add-on
         <a class="drug drug_general" data-topicid="8874" href="/z/d/drug information/8874.html" rel="external">
          citalopram
         </a>
         in patients (n = 104) who did not respond to initial treatment with
         <a class="drug drug_general" data-topicid="8554" href="/z/d/drug information/8554.html" rel="external">
          imipramine
         </a>
         [
         <a href="#rid19">
          19
         </a>
         ]. Lithium target serum levels were 0.6 to 0.8 mEq/L and citalopram was titrated up to 30 mg/day. Remission occurred in fewer patients who received lithium than citalopram than lithium (21 versus 40 percent).
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H11208500">
         <span class="h2">
          Dose and serum level
         </span>
         <span class="headingEndMark">
          —
         </span>
         We suggest clinicians initially prescribe adjunctive
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         300 or 600 mg once per day. The dose should be increased every one to five days depending on how well it is tolerated, to an eventual target dose of 600 to 1200 mg per day, or a dose sufficient to achieve 12-hour serum levels of 0.6 to 0.9 mEq/L (0.6 to 0.9 mmol/L) [
         <a href="#rid20">
          20-22
         </a>
         ].
        </p>
        <p>
         One study compared
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         750 mg per day versus 250 mg per day as adjunctive treatment in 34 patients with unipolar major depression who did not respond to treatment with a tricyclic antidepressant [
         <a href="#rid23">
          23
         </a>
         ]. Significantly more patients responded (50 percent or more decrease in the depression rating scale score) with 750 mg per day (44 versus 18 percent).
        </p>
        <p>
         A meta-analysis of nine controlled trials (234 patients) found no evidence for a dose response relationship beyond 800 mg daily [
         <a href="#rid24">
          24
         </a>
         ]. A second meta-analysis of 10 controlled trials (269 patients) found that
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         augmentation was significantly more efficacious compared with placebo, with lithium generally prescribed at a dose of 900 mg/day [
         <a href="#rid7">
          7
         </a>
         ]. Serum levels generally ranged from 0.6 to 1.0 mEq/L (0.6 to 1.0 mmol/L). In a subsequent controlled trial, adjunctive lithium was started at 225 or 450 mg per day for one week and titrated up to a target dose of 900 mg per day; the final mean daily dose was 860 mg and the median serum level was 0.6 mEq/L (0.6 mmol/L) [
         <a href="#rid15">
          15
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H11208506">
         <span class="h2">
          Duration
         </span>
         <span class="headingEndMark">
          —
         </span>
         We suggest clinicians prescribe adjunctive
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         for at least four weeks before deciding whether it is helpful [
         <a href="#rid13">
          13,20
         </a>
         ]. Remission may occur as soon as one week.
        </p>
        <p>
         Evidence related to the duration of an adequate trial of add-on
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         includes a review of 27 open-label studies or randomized trials (803 depressed patients, &gt;90 percent unipolar), which estimated that 50 percent of patients responded within two to six weeks of lithium augmentation [
         <a href="#rid25">
          25,26
         </a>
         ]. In a meta-analysis that included 12 randomized trials (n = 541 depressed patients), the mean duration of treatment was four weeks [
         <a href="#rid10">
          10
         </a>
         ]. In one trial, patients with unipolar major depression were treated with adjunctive lithium for up to 14 weeks and a mean of nine weeks [
         <a href="#rid15">
          15
         </a>
         ]. Among the nine patients who eventually remitted:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Two remitted after 2 weeks of treatment
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Three after 3 to 4 weeks
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         One after 5 to 6 weeks
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         One after 7 to 12 weeks
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Two after 13 to 14 weeks
        </p>
        <p>
        </p>
        <p>
         Another study found that depression rating scale scores began to decline in week one of treatment with adjunctive
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         and steadily decreased during six weeks of treatment [
         <a href="#rid23">
          23
         </a>
         ].
        </p>
        <p>
         Patients who respond to
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         augmentation should be maintained on the lithium-antidepressant combination for at least one year [
         <a href="#rid25">
          25,27
         </a>
         ]. The largest controlled trial that examined this issue studied 29 patients with unipolar major depression who initially did not respond to antidepressant monotherapy (primarily tricyclics), but subsequently remitted with adjunctive lithium [
         <a href="#rid28">
          28
         </a>
         ]. All patients then continued their antidepressant and were randomly assigned to continue adjunctive lithium or to receive placebo for four months. Relapse occurred in significantly fewer patients who received lithium compared with placebo (0 versus 46 percent). Afterwards, the 14 patients who had received lithium plus an antidepressant were tapered off all their medication, which led to recurrence of depression in five patients during six months of follow-up [
         <a href="#rid29">
          29
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2519580192">
         <span class="h2">
          Contraindications
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          Lithium
         </a>
         is contraindicated in patients with:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Significant renal impairment
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sodium depletion
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Dehydration
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Significant cardiovascular disease
        </p>
        <p>
        </p>
        <p>
         Contraindications and precautions are discussed in greater detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/679.html" rel="external">
          "Bipolar mania and hypomania in adults: Choosing pharmacotherapy", section on 'Lithium'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2519580450">
         <span class="h2">
          Drug interactions
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          Lithium
         </a>
         interacts with many drugs. Medications that decrease renal lithium excretion and are particularly prone to increase serum levels with possible toxicity are:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Thiazide diuretics
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Nonsteroidal anti-inflammatory drugs
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Angiotensin converting enzyme inhibitors
        </p>
        <p>
        </p>
        <p>
         Drug interactions with
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         are discussed in greater depth elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/679.html" rel="external">
          "Bipolar mania and hypomania in adults: Choosing pharmacotherapy", section on 'Lithium'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2519581674">
         <span class="h2">
          Laboratory monitoring
         </span>
         <span class="headingEndMark">
          —
         </span>
         Clinicians must monitor serum
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         levels, renal function tests, and thyroid function tests. Laboratory monitoring is discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/15317.html" rel="external">
          "Bipolar disorder in adults and lithium: Pharmacology, administration, and management of adverse effects", section on 'Laboratory tests and monitoring'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H11208518">
         <span class="h2">
          Side effects with lithium augmentation
         </span>
         <span class="headingEndMark">
          —
         </span>
         The combination of
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         and an antidepressant is often well tolerated. Although most controlled studies have examined lithium augmentation of tricyclic antidepressants, there is more information available about side effects that occur during lithium augmentation of an SSRI.
        </p>
        <p>
         Acute side effects of
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         augmentation are reviewed here. Side effects of lithium monotherapy and longer-term toxicity are discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/679.html" rel="external">
          "Bipolar mania and hypomania in adults: Choosing pharmacotherapy", section on 'Lithium'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2358.html" rel="external">
          "Renal toxicity of lithium"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7843.html" rel="external">
          "Lithium and the thyroid"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H11208524">
         <span class="h3">
          Added onto selective serotonin reuptake inhibitors
         </span>
         <span class="headingEndMark">
          —
         </span>
         An observational study compared 110 patients receiving
         <a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">
          fluoxetine
         </a>
         monotherapy with a matched group of 110 patients receiving fluoxetine plus
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         and found no significant differences in the number and type of adverse events during seven weeks of treatment [
         <a href="#rid30">
          30
         </a>
         ]. In addition, a review of reports with a total of 503 patients, who were treated with lithium plus an SSRI, found none of the patients suffered a serious or life-threatening adverse event [
         <a href="#rid31">
          31
         </a>
         ]. The side effects that occur most frequently during lithium augmentation of an SSRI are [
         <a href="#rid17">
          17,30,31
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Gastrointestinal distress (nausea, diarrhea)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sedation
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Tremor
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Anxiety and nervousness
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Insomnia
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Headache
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Dry mouth
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H11208530">
         <span class="h3">
          Added onto tricyclic and tetracyclic drugs
         </span>
         <span class="headingEndMark">
          —
         </span>
         The side effects that occur most frequently during
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         augmentation of a cyclic antidepressant are [
         <a href="#rid32">
          32
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Nausea
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Tremor
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Polyuria
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Dry mouth
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H11208536">
         <span class="h2">
          Mechanism of action
         </span>
         <span class="headingEndMark">
          —
         </span>
         The benefit of
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         augmentation for treating unipolar major depression may be due to synergy between lithium and the antidepressant, or to the antidepressant effect of lithium itself [
         <a href="#rid33">
          33
         </a>
         ]. In either case, the mechanism of action is unclear. Most hypotheses suggest lithium enhances serotonergic function [
         <a href="#rid27">
          27
         </a>
         ]. Pharmacogenetic studies suggest that several single nucleotide polymorphisms are involved [
         <a href="#rid33">
          33
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H11208566">
         <span class="h1">
          LITHIUM MONOTHERAPY FOR ACUTE DEPRESSION
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          Lithium
         </a>
         monotherapy may effectively treat acute unipolar depression, but there is far less evidence than there is for antidepressants [
         <a href="#rid34">
          34-36
         </a>
         ]. We do not use lithium as first-, second-, or third-line treatment for acute unipolar depression. When lithium is used to treat acute depression, we suggest it be prescribed to achieve a serum level of 0.6 to 1.2 mEq/L (0.6 to 1.2 mmol/L) based upon our clinical experience.
        </p>
        <p>
         Evidence supporting the use of
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         for acute unipolar depression includes the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A six-week controlled trial assigned 27 patients with major depression to
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         or placebo. Fewer patients who received lithium withdrew from the study as treatment failures and among patients who remained in the study, depression rating scale scores were lower at weeks four and five in patients who received lithium compared with patients who received placebo [
         <a href="#rid34">
          34
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A meta-analysis of four controlled studies, in which 148 patients were treated for three weeks with either
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         at a serum level of 0.4 to 1.5 mEq/L (0.4 to 1.5 mmol/L) or with an antidepressant, found a moderate clinical effect favoring lithium [
         <a href="#rid35">
          35
         </a>
         ]. A subsequent randomized trial compared lithium with
         <a class="drug drug_general" data-topicid="9283" href="/z/d/drug information/9283.html" rel="external">
          clomipramine
         </a>
         in patients with depression and found that efficacy was comparable [
         <a href="#rid36">
          36
         </a>
         ]. However, the lack of a placebo arm makes it more difficult to interpret the treatment effects observed in these studies. In addition, no randomized trials have compared lithium with selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors,
         <a class="drug drug_general" data-topicid="9656" href="/z/d/drug information/9656.html" rel="external">
          mirtazapine
         </a>
         , or
         <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">
          bupropion
         </a>
         for treating acute unipolar depression.
        </p>
        <p>
        </p>
        <p>
         There are no established predictors for
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         ’s acute antidepressant effect. Lithium may be more effective for bipolar depression compared with unipolar depression, thus, a family history of bipolar depression may possibly predict a better outcome for lithium’s efficacy in acute unipolar depression [
         <a href="#rid37">
          37,38
         </a>
         ].
        </p>
        <p>
         However, the recurrent or cyclical nature of the mood disorder may be associated with a positive response to
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         , rather than polarity. In a prospective observational study of 30 patients with acute unipolar major depression who were treated for four weeks, response (reduction of baseline symptoms ≥50 percent) occurred in more patients with a recurrent episode than patients with a first lifetime episode (15 of 22 versus 0 of 8 patients [68 versus 0 percent]) [
         <a href="#rid39">
          39
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H11208572">
         <span class="h1">
          LITHIUM MONOTHERAPY AS MAINTENANCE TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          Lithium
         </a>
         prevents recurrence of unipolar depression.
        </p>
        <p>
         Three meta-analyses of randomized trials have established that
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         monotherapy is more efficacious than placebo as maintenance treatment:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         One meta-analysis of eight trials (263 patients with unipolar depression) found that recurrence of depression occurred in fewer patients who received
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         compared with patients who received placebo (34 versus 67 percent) [
         <a href="#rid35">
          35
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A subsequent meta-analysis of a nine trials (229 patients with unipolar depression) also found that recurrence of depression occurred in fewer patients who received
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         compared with patients who received placebo (36 versus 75 percent) [
         <a href="#rid40">
          40
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the third meta-analysis, which included seven trials that lasted 15 to 112 weeks (n = 233 patients with unipolar major depression), the likelihood of remaining euthymic was greater with
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         than placebo (odds ratio 4.5, 95% CI 1.4-14.5) [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Three meta-analyses have compared the efficacy of
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         monotherapy with an antidepressant as maintenance treatment:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         One meta-analysis of seven randomized trials (298 patients with unipolar depression) found that recurrence of depression occurred in a similar number of patients who received
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         compared with patients who received a tricyclic antidepressant (48 versus 56 percent) [
         <a href="#rid35">
          35
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A subsequent meta-analysis of eight trials (475 patients, the large majority had unipolar depression) also compared the efficacy of
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         with antidepressants in preventing recurrence [
         <a href="#rid41">
          41
         </a>
         ]. One analysis that defined recurrence as admission to the hospital (three studies with 152 patients) found recurrence of depression occurred in significantly fewer patients who received lithium compared with patients who received an antidepressant (7 versus 22 percent). Analyses that used different definitions of recurrence found that the rate of recurrence was comparable for patients who received lithium and patients who received an antidepressant. In addition, there were no significant differences between lithium and antidepressants in the overall drop-out rate (as a proxy measure of overall acceptability of treatment), drop-out due to side effects, and number of patients who reported at least one side effect. The lack of a placebo arm makes it more difficult to interpret the treatment effects observed in these studies.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the third meta-analysis, which included five trials that lasted 56 to 130 weeks (n = 224 patients with unipolar major depression), the likelihood of remaining euthymic was comparable in patients who received
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         or antidepressants (odds ratio 2.2, 95% CI 0.7-7.1) [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Using
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         to prevent recurrence of unipolar depression is consistent with the American Psychiatric Association Practice Guidelines for Major Depressive Disorder [
         <a href="#rid42">
          42
         </a>
         ] and treatment guidelines from the British Association for Psychopharmacology [
         <a href="#rid43">
          43
         </a>
         ].
        </p>
        <p>
         Based upon the serum levels used in randomized trials and our clinical experience, we suggest clinicians prescribe
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         to achieve a serum level of 0.6 to 1.2 mEq/L (0.6 to 1.2 mmol/L). There are no established factors that predict response to maintenance treatment with lithium monotherapy.
        </p>
        <p class="headingAnchor" id="H11208578">
         <span class="h1">
          PREVENTING SUICIDE
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          Lithium
         </a>
         may reduce the risk of suicide in patients with mood disorders, including recurrent unipolar major depression. (See
         <a class="medical medical_review" href="/z/d/html/1708.html" rel="external">
          "Suicidal ideation and behavior in adults", section on 'Pharmacotherapy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4188694762">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/116503.html" rel="external">
          "Society guideline links: Depressive disorders"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H11208584">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Add-on
         </strong>
         <strong>
          lithium
         </strong>
         <strong>
          for treatment-resistant depression
         </strong>
         –
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          Lithium
         </a>
         is superior to placebo as augmentation for an antidepressant that does not adequately treat a depressive syndrome. Clinicians should initially prescribe adjunctive lithium 300 mg per day or 300 mg twice per day. The dose should be increased every one or two days depending on how well it is tolerated, to an eventual target dose of 900 mg per day, or a dose to achieve 12-hour serum levels of 0.6 to 0.9 mEq/L (0.6 to 0.9 mmol/L).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Only a few controlled trials have compared the efficacy of
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         with other drugs for augmenting an antidepressant that has inadequately treated a depressive syndrome, but the limited data suggest that lithium is comparable to
         <sub>
         </sub>
         T3
         <sub>
         </sub>
         (triiodothyronine) or a second antidepressant. (See
         <a class="local">
          'Add-on lithium for treatment-resistant depression'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Lithium
         </strong>
         <strong>
          monotherapy
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Acute depression
         </strong>
         –
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          Lithium
         </a>
         monotherapy may effectively treat acute unipolar depression, but the evidence is limited. (See
         <a class="local">
          'Lithium monotherapy for acute depression'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Maintenance treatment
         </strong>
         –
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          Lithium
         </a>
         monotherapy prevents recurrent episodes of unipolar depression. Lithium maintenance treatment generally requires a serum level of 0.6 to 1.2 mEq/L (0.6 to 1.2 mmol/L). (See
         <a class="local">
          'Lithium monotherapy as maintenance treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Preventing suicide
         </strong>
         –
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          Lithium
         </a>
         may reduce the risk of suicide in patients with recurrent unipolar major depression. (See
         <a class="medical medical_review" href="/z/d/html/1708.html" rel="external">
          "Suicidal ideation and behavior in adults", section on 'Pharmacotherapy'
         </a>
         .)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Dé Montigny C, Grunberg F, Mayer A, Deschenes JP. Lithium induces rapid relief of depression in tricyclic antidepressant drug non-responders. Br J Psychiatry 1981; 138:252.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shorter E. The history of lithium therapy. Bipolar Disord 2009; 11 Suppl 2:4.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006; 163:28.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thase ME, Haight BR, Richard N, et al. Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomized controlled trials. J Clin Psychiatry 2005; 66:974.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thase ME, Nierenberg AA, Vrijland P, et al. Remission with mirtazapine and selective serotonin reuptake inhibitors: a meta-analysis of individual patient data from 15 controlled trials of acute phase treatment of major depression. Int Clin Psychopharmacol 2010; 25:189.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hirschfeld RM, Montgomery SA, Aguglia E, et al. Partial response and nonresponse to antidepressant therapy: current approaches and treatment options. J Clin Psychiatry 2002; 63:826.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Crossley NA, Bauer M. Acceleration and augmentation of antidepressants with lithium for depressive disorders: two meta-analyses of randomized, placebo-controlled trials. J Clin Psychiatry 2007; 68:935.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nelson JC, Baumann P, Delucchi K, et al. A systematic review and meta-analysis of lithium augmentation of tricyclic and second generation antidepressants in major depression. J Affect Disord 2014; 168:269.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhou X, Ravindran AV, Qin B, et al. Comparative efficacy, acceptability, and tolerability of augmentation agents in treatment-resistant depression: systematic review and network meta-analysis. J Clin Psychiatry 2015; 76:e487.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Undurraga J, Sim K, Tondo L, et al. Lithium treatment for unipolar major depressive disorder: Systematic review. J Psychopharmacol 2019; 33:167.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vázquez GH, Bahji A, Undurraga J, et al. Efficacy and Tolerability of Combination Treatments for Major Depression: Antidepressants plus Second-Generation Antipsychotics vs. Esketamine vs. Lithium. J Psychopharmacol 2021; 35:890.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Buspavanich P, Behr J, Stamm T, et al. Treatment response of lithium augmentation in geriatric compared to non-geriatric patients with treatment-resistant depression. J Affect Disord 2019; 251:136.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vermeiden M, Kamperman AM, Hoogendijk WJG, et al. A randomized clinical trial comparing two two-phase treatment strategies for in-patients with severe depression. Acta Psychiatr Scand 2017; 136:118.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Valenstein M, McCarthy JF, Austin KL, et al. What happened to lithium? Antidepressant augmentation in clinical settings. Am J Psychiatry 2006; 163:1219.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nierenberg AA, Fava M, Trivedi MH, et al. A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report. Am J Psychiatry 2006; 163:1519.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Joffe RT, Singer W, Levitt AJ, MacDonald C. A placebo-controlled comparison of lithium and triiodothyronine augmentation of tricyclic antidepressants in unipolar refractory depression. Arch Gen Psychiatry 1993; 50:387.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fava M, Alpert J, Nierenberg A, et al. Double-blind study of high-dose fluoxetine versus lithium or desipramine augmentation of fluoxetine in partial responders and nonresponders to fluoxetine. J Clin Psychopharmacol 2002; 22:379.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fava M, Rosenbaum JF, McGrath PJ, et al. Lithium and tricyclic augmentation of fluoxetine treatment for resistant major depression: a double-blind, controlled study. Am J Psychiatry 1994; 151:1372.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Navarro V, Boulahfa I, Obach A, et al. Lithium Augmentation Versus Citalopram Combination in Imipramine-Resistant Major Depression: A 10-Week Randomized Open-Label Study. J Clin Psychopharmacol 2019; 39:254.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kennedy SH, Lam RW, McIntyre RS, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological Treatments. Can J Psychiatry 2016; 61:540.
          </a>
         </li>
         <li class="breakAll">
          Department of Veterans Affairs. VA/DoD Clinical Practice Guideline for the Management of Major Depressive Disorder. U.S. Government Printing Office; Department of Defense, Washington, DC, 2022.
         </li>
         <li class="breakAll">
          National Institute for Health and Care Excellence (NICE). Depression in adults: treatment and management. NICE guideline [NG222]. June 29, 2022. https://www.nice.org.uk/guidance/ng222 (Accessed on March 15, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stein G, Bernadt M. Lithium augmentation therapy in tricyclic-resistant depression. A controlled trial using lithium in low and normal doses. Br J Psychiatry 1993; 162:634.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bauer M, Dopfmer S. Lithium augmentation in treatment-resistant depression: meta-analysis of placebo-controlled studies. J Clin Psychopharmacol 1999; 19:427.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bauer M, Forsthoff A, Baethge C, et al. Lithium augmentation therapy in refractory depression-update 2002. Eur Arch Psychiatry Clin Neurosci 2003; 253:132.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bauer M, Adli M, Baethge C, et al. Lithium augmentation therapy in refractory depression: clinical evidence and neurobiological mechanisms. Can J Psychiatry 2003; 48:440.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bschor T, Bauer M. Efficacy and mechanisms of action of lithium augmentation in refractory major depression. Curr Pharm Des 2006; 12:2985.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bauer M, Bschor T, Kunz D, et al. Double-blind, placebo-controlled trial of the use of lithium to augment antidepressant medication in continuation treatment of unipolar major depression. Am J Psychiatry 2000; 157:1429.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bschor T, Berghöfer A, Ströhle A, et al. How long should the lithium augmentation strategy be maintained? A 1-year follow-up of a placebo-controlled study in unipolar refractory major depression. J Clin Psychopharmacol 2002; 22:427.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bauer M, Linden M, Schaaf B, Weber HJ. Adverse events and tolerability of the combination of fluoxetine/lithium compared with fluoxetine. J Clin Psychopharmacol 1996; 16:130.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hawley CJ, Loughlin PJ, Quick SJ, et al. Efficacy, safety and tolerability of combined administration of lithium and selective serotonin reuptake inhibitors: a review of the current evidence. Hertfordshire Neuroscience Research Group. Int Clin Psychopharmacol 2000; 15:197.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zusky PM, Biederman J, Rosenbaum JF, et al. Adjunct low dose lithium carbonate in treatment-resistant depression: a placebo-controlled study. J Clin Psychopharmacol 1988; 8:120.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bauer M, Adli M, Bschor T, et al. Lithium's emerging role in the treatment of refractory major depressive episodes: augmentation of antidepressants. Neuropsychobiology 2010; 62:36.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khan MC, Wickham EA, Reed JV. Lithium versus placebo in acute depression: a clinical trial. Int Clin Psychopharmacol 1987; 2:47.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Souza FG, Goodwin GM. Lithium treatment and prophylaxis in unipolar depression: a meta-analysis. Br J Psychiatry 1991; 158:666.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Linder J, Fyrö B, Pettersson U, Werner S. Acute antidepressant effect of lithium is associated with fluctuation of calcium and magnesium in plasma. A double-blind study on the antidepressant effect of lithium and clomipramine. Acta Psychiatr Scand 1989; 80:27.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mendels J, Ramsey TA, Dyson WL, Frazer A. Lithium as an antidepressant. Arch Gen Psychiatry 1979; 36:845.
          </a>
         </li>
         <li class="breakAll">
          Bauer, M, Crossley, et al. The acute antidepressive effects of lithium: from monotherapy to augmentation therapy in major depression. In: Lithium in Neuropsychiatry, Bauer, et al (Eds), Informa UK Ltd, United Kingdom 2006. p.109.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bschor T, Uhr M, Baethge C, et al. Acute antidepressive efficacy of lithium monotherapy, not citalopram, depends on recurrent course of depression. J Clin Psychopharmacol 2013; 33:38.
          </a>
         </li>
         <li class="breakAll">
          Davis, JM. Lithium maintenance of unipolar depression. In: Lithium in Neuropsychiatry: The Comprehensive Guide, Bauer, M, Grof, P, Muller-Oerlinghausen, B (Eds), Informa UK Ltd, 2006. p.99.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cipriani A, Smith K, Burgess S, et al. Lithium versus antidepressants in the long-term treatment of unipolar affective disorder. Cochrane Database Syst Rev 2006; :CD003492.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           American Psychiatric Association. Practice guidelines for the treatment of patients with major depressive disorder, third edition. Am J Psychiatry 2010; 167:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cleare A, Pariante CM, Young AH, et al. Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines. J Psychopharmacol 2015; 29:459.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 13506 Version 21.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7272619" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Lithium induces rapid relief of depression in tricyclic antidepressant drug non-responders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19538681" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : The history of lithium therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16390886" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16086611" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomized controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20531012" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Remission with mirtazapine and selective serotonin reuptake inhibitors: a meta-analysis of individual patient data from 15 controlled trials of acute phase treatment of major depression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12363125" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Partial response and nonresponse to antidepressant therapy: current approaches and treatment options.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17592920" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Acceleration and augmentation of antidepressants with lithium for depressive disorders: two meta-analyses of randomized, placebo-controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25069082" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : A systematic review and meta-analysis of lithium augmentation of tricyclic and second generation antidepressants in major depression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25919841" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Comparative efficacy, acceptability, and tolerability of augmentation agents in treatment-resistant depression: systematic review and network meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30698058" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Lithium treatment for unipolar major depressive disorder: Systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34238049" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Efficacy and Tolerability of Combination Treatments for Major Depression: Antidepressants plus Second-Generation Antipsychotics vs. Esketamine vs. Lithium.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30921597" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Treatment response of lithium augmentation in geriatric compared to non-geriatric patients with treatment-resistant depression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28478653" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : A randomized clinical trial comparing two two-phase treatment strategies for in-patients with severe depression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16816227" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : What happened to lithium? Antidepressant augmentation in clinical settings.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16946176" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8489327" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : A placebo-controlled comparison of lithium and triiodothyronine augmentation of tricyclic antidepressants in unipolar refractory depression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12172337" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Double-blind study of high-dose fluoxetine versus lithium or desipramine augmentation of fluoxetine in partial responders and nonresponders to fluoxetine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8067495" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Lithium and tricyclic augmentation of fluoxetine treatment for resistant major depression: a double-blind, controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30925498" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Lithium Augmentation Versus Citalopram Combination in Imipramine-Resistant Major Depression: A 10-Week Randomized Open-Label Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27486148" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological Treatments.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27486148" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological Treatments.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27486148" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological Treatments.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8149115" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Lithium augmentation therapy in tricyclic-resistant depression. A controlled trial using lithium in low and normal doses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10505584" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Lithium augmentation in treatment-resistant depression: meta-analysis of placebo-controlled studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12904977" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Lithium augmentation therapy in refractory depression-update 2002.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12971013" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Lithium augmentation therapy in refractory depression: clinical evidence and neurobiological mechanisms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16918427" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Efficacy and mechanisms of action of lithium augmentation in refractory major depression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10964859" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Double-blind, placebo-controlled trial of the use of lithium to augment antidepressant medication in continuation treatment of unipolar major depression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12172345" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : How long should the lithium augmentation strategy be maintained? A 1-year follow-up of a placebo-controlled study in unipolar refractory major depression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8690828" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Adverse events and tolerability of the combination of fluoxetine/lithium compared with fluoxetine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10954059" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Efficacy, safety and tolerability of combined administration of lithium and selective serotonin reuptake inhibitors: a review of the current evidence. Hertfordshire Neuroscience Research Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3131389" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Adjunct low dose lithium carbonate in treatment-resistant depression: a placebo-controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20453533" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Lithium's emerging role in the treatment of refractory major depressive episodes: augmentation of antidepressants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3117877" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Lithium versus placebo in acute depression: a clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1830506" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Lithium treatment and prophylaxis in unipolar depression: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2669444" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Acute antidepressant effect of lithium is associated with fluctuation of calcium and magnesium in plasma. A double-blind study on the antidepressant effect of lithium and clomipramine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/454103" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Lithium as an antidepressant.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/454103" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Lithium as an antidepressant.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23277245" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Acute antidepressive efficacy of lithium monotherapy, not citalopram, depends on recurrent course of depression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23277245" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Acute antidepressive efficacy of lithium monotherapy, not citalopram, depends on recurrent course of depression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17054174" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Lithium versus antidepressants in the long-term treatment of unipolar affective disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Practice guidelines for the treatment of patients with major depressive disorder, third edition
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25969470" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
